Vandin Fabio
Department of Information Engineering, University of PadovaPadova, Italy.
Front Genet. 2017 Jun 14;8:83. doi: 10.3389/fgene.2017.00083. eCollection 2017.
Advances in DNA sequencing technologies have allowed the characterization of somatic mutations in a large number of cancer genomes at an unprecedented level of detail, revealing the extreme genetic heterogeneity of cancer at two different levels: inter-tumor, with different patients of the same cancer type presenting different collections of somatic mutations, and intra-tumor, with different clones coexisting within the same tumor. Both inter-tumor and intra-tumor heterogeneity have crucial implications for clinical practices. Here, we review computational methods that use somatic alterations measured through next-generation DNA sequencing technologies for characterizing tumor heterogeneity and its association with clinical variables. We first review computational methods for studying inter-tumor heterogeneity, focusing on methods that attempt to summarize cancer heterogeneity by discovering pathways that are commonly mutated across different patients of the same cancer type. We then review computational methods for characterizing intra-tumor heterogeneity using information from bulk sequencing data or from single cell sequencing data. Finally, we present some of the recent computational methodologies that have been proposed to identify and assess the association between inter- or intra-tumor heterogeneity with clinical variables.
DNA测序技术的进步使得人们能够以前所未有的详细程度对大量癌症基因组中的体细胞突变进行表征,揭示了癌症在两个不同层面的极端遗传异质性:肿瘤间异质性,即同一癌症类型的不同患者呈现出不同的体细胞突变集合;肿瘤内异质性,即同一肿瘤内共存着不同的克隆。肿瘤间和肿瘤内的异质性对临床实践都具有至关重要的意义。在此,我们综述了一些计算方法,这些方法利用通过下一代DNA测序技术测得的体细胞改变来表征肿瘤异质性及其与临床变量的关联。我们首先综述用于研究肿瘤间异质性的计算方法,重点关注那些试图通过发现同一癌症类型不同患者中共同发生突变的通路来总结癌症异质性的方法。然后,我们综述利用来自批量测序数据或单细胞测序数据的信息来表征肿瘤内异质性的计算方法。最后,我们介绍一些最近提出的用于识别和评估肿瘤间或肿瘤内异质性与临床变量之间关联的计算方法。